The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.
 
Ian Flinn
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Gilead Sciences (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Nurix (Inst); Roche (Inst); Seagen (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
Mazyar Shadman
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Atara Biotherapeutics; Cellectar; Genentech; Sound Biologics; Verastem
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Emergent BioSolutions (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Benjamin Bruce Freeman
No Relationships to Disclose
 
Dih-Yih Chen
Employment - Acerta Pharma/AstraZeneca; BeiGene
Stock and Other Ownership Interests - BeiGene
 
Xiaoping Zhang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Aileen Cohen
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Sunhee K. Ro
Employment - BeiGene
Stock and Other Ownership Interests - Amgen; BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Jane Huang
Employment - BeiGene
Leadership - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Jeff P. Sharman
Consulting or Advisory Role - Abbvie; Acerta Pharma; AstraZeneca; Celgene; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie; Acerta Pharma; AstraZeneca; Celgene; Pharmacyclics; TG Therapeutics